"We are leaders in national and global research, focused on neurological disorders. We offer high impact clinical trial opportunities in Parkinson’s Disease, Huntington’s Disease, Multiple Sclerosis, Alzheimer’s Disease and other forms of dementia. We take great pride in helping those with neurological disorders navigate through clinical trial participation, and explore options that are the best fit for their needs."

During the past decade, Inland Northwest Research conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 10 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 10 clinical trials were completed. i.e. 47.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Inland Northwest Research" #1 sponsor was "Biogen" with 3 trials, followed by "Theravance Biopharma" with 3 trials sponsored, "ACADIA Pharmaceuticals Inc." with 2 trials sponsored, "Abbott Medical Devices" with 2 trials sponsored and "Impax Laboratories, LLC" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Inland Northwest Research" #1 collaborator was "Michael J. Fox Foundation for Parkinson's Research" with 3 trials as a collaborator, "University of Rochester" with 2 trials as a collaborator, "Denali Therapeutics Inc." with 1 trials as a collaborator, "Fulgent Genetics" with 1 trials as a collaborator and "Indiana University" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Inland Northwest Research" are "Parkinson Disease" (9 trials), "Parkinson's Disease" (6 trials), "Symptomatic Neurogenic Orthostatic Hypotension" (3 trials), "Essential Tremor" (2 trials) and "Parkinson Disease Psychosis" (2 trials). Many other conditions were trialed in "Inland Northwest Research" in a lesser frequency.

Most popular intervention types in "Inland Northwest Research" are "Drug" (22 trials), "Device" (5 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "ampreloxetine" (3 trials), "ATA188" (1 trials), "ATH-1017" (1 trials) and "BIIB054" (1 trials). Other intervention names were less common.

The vast majority of trials in "Inland Northwest Research" are 30 trials for "All" genders.

Currently, there are NaN active trials in "Inland Northwest Research". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Inland Northwest Research, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Inland Northwest Research, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".